Glutamine Inhibition: A Universal BioWeapon Against Cancer?

 Glutamine Inhibition: A Universal BioWeapon Against Cancer?

An extraordinary series of experiments reveals a potentially exploitable difference in energy metabolism between certain cancer cells and normal cells.

Every living cell needs energy to survive. This energy is supplied primarily in the form of ATP (adenosine triphosphate) made in the mitochondria which powers thousands of biochemical, biomechanical, and bioelectrical processes essential for life.

Nature has evolved several mechanisms to generate ATP.

The most efficient is oxidative phosphorylation (OxPhos), which takes place inside mitochondria. Normal cells with functioning mitochondria can use glucose, fatty acids, ketone bodies, and other substrates to generate ATP.

But what if cancer cells cannot generate sufficient ATP through OxPhos alone?

What if their survival depends on two particular fuels—glucose and glutamine—and depriving them of these fuels causes an energy crisis that normal cells can better withstand?

Professor Thomas Seyfried and his collaborators have spent years investigating this possibility.

I became a huge fan of Professor Thomas Seyfried since I read his line and almost fell of my chair: “You can't get cancer if your mitochondria are healthy.”

Their findings are extraordinary.

THE EXTRAORDINARY DISCOVERY: OXPHOS ALONE WAS INSUFFICIENT

In December 2024, Seyfried and ten collaborators published Amino Acid and Glucose Fermentation Maintain ATP Content in Mouse and Human Malignant Glioma Cells in ASN Neuro.

The researchers investigated three malignant glioma cell lines: VM-M3 and CT-2A from mice, and U-87MG from humans.

Despite differences in species origin, genetic background, and biological characteristics, the cells exhibited a remarkable commonality.

OxPhos alone was insufficient to maintain their ATP content when glucose and glutamine were absent.

Yet the cells could maintain ATP when glutamine was available, even under conditions that severely restricted oxidative phosphorylation.

The researchers concluded that OxPhos was neither necessary nor sufficient for growth in these glioma models under the experimental conditions.

Could we deprive cancer cells of the fuels they cannot survive without, while allowing normal cells to continue generating ATP through OxPhos?

HOW SEYFRIED ESTABLISHED HIS HYPOTHESIS

The researchers did not merely observe that cancer cells consumed large quantities of glucose and glutamine.

They manipulated the availability of oxygen, glucose, amino acids, and mitochondrial respiratory activity while measuring ATP content.

The following experiments were reported in the 2024 study by Lee, Seyfried, and colleagues.

Experiment 1: Remove glucose and supply glutamine

The researchers cultured glioma cells without glucose while providing glutamine.

Remarkably, glutamine maintained substantial cellular ATP content for up to 24 hours.

This demonstrated that glucose-dependent glycolysis was not the only mechanism capable of sustaining ATP in these cells.

Experiment 2: Severely restrict oxygen

The investigators exposed the glioma cells to approximately 0.1% oxygen.

OxPhos requires oxygen as the final electron acceptor in the mitochondrial respiratory chain.

Yet glutamine continued to support ATP maintenance under severe hypoxia.

This supported the existence of an important ATP-generating mechanism that did not directly depend on conventional OxPhos.

Experiment 3: Inhibit mitochondrial respiration

The researchers used complex IV inhibitors, including cyanide and azide, to investigate the relationship between mitochondrial respiration and ATP production.

They demonstrated that oxygen consumption could not reliably quantify the contribution of OxPhos to ATP production in these cells.

The presence of respiratory activity did not mean that OxPhos alone could meet the cells’ energy requirements.

Experiment 4: Investigate alternative amino acids

The researchers tested whether amino acids other than glutamine could sustain ATP.

Glutamine and glutamate were especially effective, while other tested amino acids could not adequately substitute for them.

This pointed toward a particularly important role for glutamine-derived carbon in maintaining cellular ATP.

Experiment 5: Block glutamine metabolism

The investigators used 6-diazo-5-oxo-L-norleucine (DON), an inhibitor of multiple glutamine-utilizing enzymes.

Inhibition of glutamine metabolism reduced ATP content and succinate export.

The findings supported the hypothesis that glutamine contributed to ATP generation through mitochondrial substrate-level phosphorylation.

Experiment 6: Examine ATP maintenance without glucose and glutamine

The combined experiments demonstrated that mitochondrial respiration alone was insufficient to maintain ATP content when both major fermentable fuels were absent.

The researchers interpreted the results as evidence that glucose and glutamine fermentation were essential contributors to ATP maintenance in these malignant glioma models.

These observations, together with earlier theoretical and experimental work described in On the Origin of ATP Synthesis in Cancer (Seyfried et al., 2020), support further investigation of fermentation-dependent energy metabolism as a therapeutic vulnerability.

HOW GLUTAMINE GENERATES ATP WITHOUT OXPHOS

Glutamine is the most abundant free amino acid in human blood.

Besides providing nitrogen and carbon for biosynthesis, glutamine can replenish mitochondrial metabolic intermediates and support ATP production.

The pathway is particularly interesting because one of its reactions can generate ATP or GTP directly, without requiring the mitochondrial electron transport chain.

Step 1: Glutamine enters the cell.

Glutamine is transported into the cell through amino acid transporters.

Step 2: Glutamine is converted into glutamate.

The enzyme glutaminase (GLS) converts glutamine into glutamate, releasing ammonia.

Glutamine → Glutamate

Step 3: Glutamate becomes alpha-ketoglutarate.

Glutamate is converted into alpha-ketoglutarate (α-KG) through glutamate dehydrogenase or aminotransferase reactions.

Glutamate → α-Ketoglutarate

Step 4: Alpha-ketoglutarate becomes succinyl-CoA.

The alpha-ketoglutarate dehydrogenase complex converts α-KG into succinyl-CoA, producing NADH and releasing carbon dioxide.

α-Ketoglutarate → Succinyl-CoA

Step 5: Succinyl-CoA becomes succinate, generating ATP or GTP.

This is the crucial reaction.

The enzyme succinyl-CoA synthetase converts succinyl-CoA into succinate.

The reaction generates ATP or GTP, depending on the enzyme isoform. GTP can subsequently be used to generate ATP.

This mechanism is called mitochondrial substrate-level phosphorylation (mSLP).

Succinyl-CoA → Succinate + ATP/GTP

Unlike OxPhos, the ATP-generating reaction does not directly require oxygen.

However, sustained flux through this pathway still requires the cell to maintain appropriate substrate availability and redox balance.

The overall simplified pathway is:

Glutamine → Glutamate → α-Ketoglutarate → Succinyl-CoA → Succinate

ATP or GTP is generated during the final conversion.

The significance of this pathway in cancer metabolism is discussed in Seyfried and colleagues’ 2020 paper in iScience.

Glutamine can also fuel OxPhos in cells with functional respiration. Therefore, glutamine dependence does not automatically prove the absence of oxidative ATP production.

But Seyfried’s glioma experiments suggest that glutamine-dependent substrate-level phosphorylation can be particularly important when OxPhos is restricted.

WHY NORMAL CELLS MAY SURVIVE WHILE CANCER CELLS RUN OUT OF ATP

Many normal cells possess considerable metabolic flexibility.

When glucose availability declines, they can increase their utilization of fatty acids.

Fatty acids undergo beta-oxidation, generating acetyl-CoA and reducing equivalents that support ATP production through OxPhos.

The liver can also produce ketone bodies, which provide alternative energy substrates for several tissues.

Normal cells with healthy mitochondria may therefore continue producing ATP even when glucose availability is reduced.

In contrast, cancer cells that depend critically on glucose and glutamine fermentation may experience a severe energy deficit when both pathways are inhibited.

This distinction forms the foundation of Seyfried’s metabolic approach to cancer, described in his 2017 paper on press-pulse therapy.

THE ANIMAL EXPERIMENTS PROVIDE AN IMPORTANT CLUE

In 2019, Seyfried and collaborators published Therapeutic benefit of combining calorie-restricted ketogenic diet and glutamine targeting in late-stage experimental glioblastoma in Communications Biology.

The researchers investigated two aggressive mouse glioblastoma models, VM-M3 and CT-2A.

They combined two interventions.

The first was a calorie-restricted ketogenic diet intended to reduce circulating glucose while increasing ketone bodies.

The second was DON (6-Diazo-5-oxo-L-norleucine) a pharmaceutical inhibitor of glutamine-utilizing enzymes.

The results were striking.

In the VM-M3 model, the combination produced substantially greater antitumor activity than either intervention alone.

In one experiment, tumor bioluminescence was approximately 75% lower in the combined-treatment group than in groups receiving either intervention alone.

In another experiment, seven of eight DON-treated mice receiving the restricted ketogenic diet showed tumor bioluminescence near baseline.

The combination also improved survival.

The researchers observed reduced tumor burden, inflammation, brain swelling, and other disease-associated abnormalities.

Importantly, DON was administered according to intermittent experimental schedules rather than requiring indefinite continuous inhibition.

The study also found that the ketogenic dietary intervention increased DON concentrations in tumor tissue.

These results provided evidence that combining glucose restriction with pharmaceutical inhibition of glutamine metabolism could produce substantial antitumor effects in mice.

The investigators reported tumor-cell death and improved survival, although the findings did not establish complete eradication of every malignant cell or a curative treatment for humans.

COULD THIS BECOME A GAME CHANGER IN CANCER MANAGEMENT?

Cancer is extraordinarily complex.

Thousands of mutations, epigenetic alterations, abnormal signaling pathways, and interactions with surrounding tissues contribute to its survival.

But beneath this complexity lies a fundamental requirement shared by every cancer cell.

It must continuously generate sufficient ATP and obtain the molecular building blocks required for survival and proliferation.

Seyfried’s research suggests that certain malignant cells possess a metabolic vulnerability that may be exploited without needing to correct every mutation or every abnormal signaling pathway.

The extraordinary finding from the 2024 experiments is that OxPhos alone was insufficient to maintain ATP in the three glioma cell lines studied.

Glucose and glutamine metabolism provided essential support.

The earlier animal experiments demonstrated that combining reduced glucose availability with pharmaceutical glutamine inhibition could produce substantial antitumor effects and improve survival in experimental glioblastoma.

The next challenge is to determine whether these metabolic differences can be exploited safely and selectively in humans.

The ultimate goal would be to exploit the difference between the metabolic inflexibility of susceptible cancer cells and the metabolic adaptability of normal tissues—to deprive cancer cells of essential energy pathways long enough to kill them, but not long enough to cause unacceptable damage to the patient.

If that window exists, discovering it could fundamentally change cancer management.